Torrent Pharmaceuticals Ltd. Share Price

PHARMA SECTOR SHOWING SUPER STRENGTH AMID WEAKER MARKETS

One interesting trend in the current market is the relative strength being displayed by Pharma stocks. During the COVID period, Pharma stocks had a completely different story. Despite many companies having strong fundamentals and robust businesses, the sector witnessed significant selling and several quality Pharma stocks were beaten down heavily once the initial COVID euphoria faded. Fast forward to today — the scenario looks very different. While the broader market is facing pressure, several Pharma stocks are holding their ground and continuing to show strong price action. Stocks like Divi’s Labs, Laurus Labs, Torrent Pharma, Zydus Lifesciences, Sun Pharma and Lupin are among the names showing encouraging strength. For me, the important takeaway is not simply that Pharma is rising — it is that Pharma is showing strength when the broader market is weak. That kind of relative strength often deserves attention. When the market becomes volatile, sectors that refuse to participate in the downside can potentially become the leaders when market sentiment improves. Pharma is definitely a sector I would keep on the radar for momentum and swing-trading opportunities.

Torrent Pharma Expands Renewable Energy Investment

Torrent Pharmaceuticals is increasing its investment in Torrent Urja 27 Pvt. Ltd. from ₹7.92 crore to ₹11.88 crore following an increase in the capacity of its captive hybrid power project in Gujarat. Deal Snapshot Investment: ₹11.88 crore Stake: 26% Project: Captive Solar + Wind Location: Gujarat Completion: 18–21 months Consideration: Cash Strategic Impact The investment is aimed at increasing renewable power usage in Torrent Pharma’s operations and supporting compliance with captive-user requirements under Indian electricity laws. Investor Relevance The move strengthens Torrent Pharma’s renewable-energy sourcing through a captive hybrid power project while increasing its investment commitment as project capacity expands. For information purpose only. Not investment advice.

NIFTY TECHNICAL LEVEL & DERIVATIVE ANALYSIS

NIFTY BULLISH BREAKOUT ZONE 23200 NIFTY BEARISH BREAKOUT ZONE 23000 OPEN INTEREST UPDATES IN OPTION CHAIN : HIGHER OPEN INTEREST SEEN @ 23400, 23200 CALL & 23100, 23000 PUT. AS PER DATA ANALYSIS MARKET LOOKS RANGEBOUND TO NEGATIVE. AS PER OPTION CHAIN ANALYSIS 23000 LOOKS STRONG SUPPORT LEVEL. MAXIMUM PUT WRITING SEEN @ 23000 PUT LEVEL. IF NIFTY BREAK 23000 LEVEL THAN 22700 WILL BE NEXT SUPPORT LEVEL. NEAR TERM 24200 IS STRONG RESISTANCE LEVEL. PUT CALL RATIO OF NIFTY IS 0.92 THIS PCR RATIO INDICATES CALL OPTION SELLERS ARE STILL DOMINATING IN THIS MARKET. FII LONG RATIO IN INDEX FUTURE IS 11.44% LAST SESSION FII WAS NOT ACTIVE IN DERIVATIVE MARKET. DURING MORNING SESSION AVOID INDEX TRADING AND USE SECTOR SPECIFIC APPROACH.

Torrent Pharma currently has a strong fundamental setup

Zydus and Glenmark Top Pharma Growth Charts in August

Can GLP-1 drugs change India’s productivity story?

A drug can change more than a patient’s weight. It can change how often someone misses work. A recent Danish study of Ozempic users found that long-term sick leave fell after treatment, while employment itself did not meaningfully increase. The important lesson: better health does not automatically translate into more jobs or higher income—but it may help people stay healthier and more consistently at work. Now India is running a much bigger real-world experiment. Semaglutide’s key Indian patent expired in March 2026, opening the market to a wave of cheaper generic versions. Companies including Sun Pharma, Dr. Reddy’s Laboratories, Zydus Lifesciences, Lupin, Alkem, Torrent Pharma and Natco Pharma have entered or developed products in this space. For investors, the interesting question isn't simply: “Who will sell the most GLP-1 drugs?” It is: Who can convert the GLP-1 opportunity into sustainable volumes, margins and market share? Sun Pharma